Company Profile
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
Latest News
How Lisa Su Has Positioned AMD to Be a Big AI Winner and Why the Stock Is a Buy
Share buybacks in Ericsson during the period July 20 - July 24, 2026
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside
Temenos Named One of World’s Top Fintech Companies by CNBC
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.yuhan.co.kr |
| Audit Risk | 1 |
| Board Risk | 9 |
| Overall Risk | 7 |
| Market Cap | 5.38T |
| Dividend Rate | 600 |
| Dividend Yield | 0.80% |
| Enterprise-to-Revenue | 2.52 |
| Enterprise-to-EBITDA | 31.17 |
| Ex-Dividend Date | 02/26/2026 |
| Earnings Date | |
| Earnings Call Date | |
| Earnings Average | 681.34 |
| Earnings Low | 605.68 |
| Earnings High | 757 |
| Revenue Average | 626.04B |
| Revenue Low | 604.00B |
| Revenue High | 638.00B |